BioCardia Inc Share Price Today: Live Updates & Key Insights

BioCardia Inc share price today is $1.2, up 0%. The stock opened at $1.2 against the previous close of $1.2, with an intraday high of $1.2 and low of $1.16.

BioCardia Inc Share Price Chart

BioCardia Inc

us-stock
To Invest in {{usstockname}}
us-stock

BioCardia Inc Share Price Performance

$1.2 0(0%) BCDA at 23 Mar 2026 12:10 PM Biotechnology
Lowest Today 1.16
Highest Today 1.2
Today’s Open 1.2
Prev. Close 1.2
52 Week High 3.20
52 Week Low 1.00
Day’s Range: Low 1.16 High 1.2
52-Week Range: Low 1.00 High 3.20
1 day return -
1 Week return -5.55
1 month return +6.25
3 month return -7.03
6 month return +7.69
1 year return -54.4
3 year return -95.99
5 year return -98.15
10 year return -

BioCardia Inc Institutional Holdings

Vanguard Group Inc 1.28

CM Management, LLC 1.22

Citadel Advisors Llc 0.89

Vanguard Institutional Extnd Mkt Idx Tr 0.65

Geode Capital Management, LLC 0.62

Abante Quant Value FI 0.54

Vanguard Total Stock Mkt Idx Inv 0.52

Fidelity Extended Market Index 0.47

Susquehanna International Group, LLP 0.37

Brown Advisory Holdings Inc 0.33

Wealth Enhancement Advisory Services, LLC 0.19

Commonwealth Equity Services Inc 0.17

XTX Topco Ltd 0.15

GSA Capital Partners LLP 0.11

Two Sigma Investments LLC 0.11

UBS Group AG 0.10

Spartan Total Market Index Pool G 0.06

Fidelity Series Total Market Index 0.06

Tower Research Capital LLC 0.03

Fidelity Total Market Index 0.03

Morgan Stanley - Brokerage Accounts 0.03

Pingora Partners LLC 0.03

Fidelity Nasdaq Composite Index 0.01

Citigroup Inc 0.01

Northern Trust Extended Eq Market Idx 0.01

NT Ext Equity Mkt Idx Fd - L 0.01

NT Ext Equity Mkt Idx Fd - NL 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

Bank of America Corp 0.00

Global Retirement Partners, LLC. 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

Vanguard U.S. Eq Idx £ Acc 0.00

Spartan Extended Market Index Pool F 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Blackstone Alternative Multi-Strategy I 0.00

Northern Trust Wilshire 5000 0.00

NT US Market Cap Idx Fd - L 0.00

SSgA U.S. Total Market Index Strategy 0.00

SBI Securities Co Ltd 0.00

Advisor Group Holdings, Inc. 0.00

BioCardia Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

BioCardia Inc Fundamentals

Market Cap 12.74 M

PB Ratio 4.8478

PE Ratio 0.0

Enterprise Value 8.09 M

Total Assets 3.72 M

Volume 37963

BioCardia Inc Company Financials

Annual Revenue FY23:477000 0.5M, FY22:1352000 1.4M, FY21:1015000 1.0M, FY20:145000 0.1M, FY19:710000 0.7M

Annual Profit FY23:66000 0.1M, FY22:-10549000 -10.5M, FY21:1015000 1.0M, FY20:141000 0.1M, FY19:352000 0.4M

Annual Net worth FY23:-11571000 -11.6M, FY22:-11913000 -11.9M, FY21:-12621000 -12.6M, FY20:-15005000 -15.0M, FY19:-14819000 -14.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:3000 0.0M

Quarterly Profit Q3/2025:-107000 -0.1M, Q2/2025:-1368000 -1.4M, Q1/2025:-1530000 -1.5M, Q3/2024:null 0.0M, Q2/2024:-103000 -0.1M

Quarterly Net worth Q3/2025:-1483000 -1.5M, Q2/2025:-2049000 -2.0M, Q1/2025:-2712000 -2.7M, Q3/2024:-1737000 -1.7M, Q2/2024:-1646000 -1.6M

About BioCardia Inc & investment objective

Company Information BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. It also has a development and commercialization agreement with CART-Tech, B.V. for the development of Heart3D Fusion Imaging system. BioCardia, Inc. is based in Sunnyvale, California.

Organisation Biotechnology

Employees 17

Industry Biotechnology

CEO Dr. Peter A. Altman Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

BioCardia Inc FAQs

What is the share price of BioCardia Inc today?

The current share price of BioCardia Inc is $1.2.

Can I buy BioCardia Inc shares in India?

Yes, Indian investors can buy BioCardia Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy BioCardia Inc shares in India?

You can easily invest in BioCardia Inc shares from India by:

Can I buy fractional shares of BioCardia Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of BioCardia Inc?

BioCardia Inc has a market cap of $12.74 M.

In which sector does BioCardia Inc belong?

BioCardia Inc operates in the Biotechnology sector.

What documents are required to invest in BioCardia Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of BioCardia Inc?

The PE ratio of BioCardia Inc is N/A and the PB ratio is 4.85.